Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), CLDN6 modulators(Claudin 6 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CLDN6-positive Solid Tumors | Phase 1 | JP | 18 Apr 2023 | |
CLDN6-positive Solid Tumors | Phase 1 | US | 18 Apr 2023 | |
Solid tumor | Phase 1 | JP | 18 Apr 2023 | |
Solid tumor | Phase 1 | US | 18 Apr 2023 |